Not all research in spinal cord injury involves stem cells. Other strategies include treatment to blunt the damage during the acute phase, improve conduction at the injury site, encourage regeneration after the initial injury, and rehabilitation to help compensate for incomplete recovery.
For example, methylprednisolone has been shown to slightly improve outcome when administered within the first 8 hours of injury and is routinely used. 4-Aminopyridine was shown to improve conduction in a small clinical study and is being evaluated in a larger study. An implantable device that uses low-level electrical stimulation has been shown in animal clinical studies to improve regeneration of axons and is currently being tested in human patients. Neural growth factors, neural “glues”, and various types of transplants are also at various stages.
Currently, NIH funding for spinal cord injury is running about $93 million a year. This compares to an estimated $14 billion per year total direct costs in the US. When you add in lost income (these are typically young adults) the cost of spinal cord injury is over $20 billion each year.
Christopher Reeves worked hard to increase funding for all types of research in spinal cord injury, and he was very successful in this. It would be a pity if we went backwards after his death because of politics.